Paradigm Biocapital Advisors LP Zentalis Pharmaceuticals, Inc. Call Options Transaction History
Paradigm Biocapital Advisors LP
- $2.77 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ZNTL
# of Institutions
142Shares Held
67.9MCall Options Held
48.5KPut Options Held
89.6K-
Matrix Capital Management Company, LP Waltham, MA14MShares$41.9 Million2.45% of portfolio
-
Eventide Asset Management, LLC Boston, MA8.55MShares$25.6 Million0.55% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$14.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.61MShares$13.8 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA3.11MShares$9.32 Million2.71% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $171M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...